DX-2930: Phase Ib expanded

Dyax expanded its double-blind, Phase Ib trial evaluating subcutaneous DX-2930 to include 2 additional cohorts, which will increase total enrollment to up to 36 patients. In the first 3 cohorts, 21 pa...